According to research agency IQVIA, Celltrion announced on the 7th that its Infliximab subcutaneous injection (SC) formulation therapy, Remsima SC, recorded a significant increase in market share in Germany, a key region within Europe. Remsima SC achieved a 39% market share in Germany in the fourth quarter of last year, marking a more than tenfold increase from 3% in its first year of launch in 2020.
The growth of Remsima SC in Germany was influenced by the expansion of prescriptions for Remsima’s intravenous (IV) formulation. The annual prescription volume of Remsima in the past year increased by nearly 30,000 compared to 2020. With a dual formulation effect, there has been an increase in Remsima prescriptions targeting new Infliximab patients, as well as a growing proportion of patients switching from competing products to Remsima SC, leading to expanded sales for both products.